An Outcome Assessment of a Single Institution’s Longitudinal Experience with Uveal Melanoma Patients with Liver Metastasis

Abstract

There is no FDA-approved treatment for metastatic uveal melanoma (UM) and overall outcomes are generally poor for those who develop liver metastasis. We performed a retrospective single-institution chart review on consecutive series of UM patients with liver metastasis who were treated at Thomas Jefferson University Hospital between 1971−1993 (Cohort 1, n = 80), 1998−2007 (Cohort 2, n = 198), and 2008−2017 (Cohort 3, n = 452). In total, 70% of patients in Cohort 1 received only systemic therapies as their treatment modality for liver metastasis, while 98% of patients in Cohort 2 and Cohort 3 received liver-directed treatment either alone or with systemic therapy. Median Mets-to-Death OS was shortest in Cohort 1 (5.3 months, 95% CI: 4.2−7.0), longer in Cohort 2 (13.6 months, 95% CI: 12.2−16.6) and longest in Cohort 3 (17.8 months, 95% CI: 16.6−19.4). Median Eye Tx-to-Death OS was shortest in Cohort 1 (40.8 months, 95% CI: 37.1−56.9), and similar in Cohort 2 (62.6 months, 95% CI: 54.6−71.5) and Cohort 3 (59.4 months, 95% CI: 56.2−64.7). It is speculated that this could be due to the shift of treatment modalities from DTIC-based chemotherapy to liver-directed therapies. Combination of liver-directed and newly developed systemic treatments may further improve the survival of these patients.

Keywords

• uveal melanoma
• metastatic uveal melanoma
• liver metastasis
• survival
• treatment strategy
• liver-directed treatment
• real-world data